TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06796153

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Untreated zone
Description: The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
Study: NCT06795451

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous spinal direct current stimulation
Description: transcutaneous spinal direct current stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous spinal direct current stimulation
Description: transcutaneous spinal direct current stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous spinal direct current stimulation
Description: transcutaneous spinal direct current stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous spinal direct current stimulation
Description: transcutaneous spinal direct current stimulation
Study: NCT06797154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StrokeWear Motor and Behavioral Intervention
Description: The intervention will consist of 1) the use of StrokeWear for goal directed movements (GDM) feedback and goal setting, 2) use of daily activity action planning (DAAP) to foster planned hemiparetic UE use during daily activities in the home and community, and 3) patient empowerment. Patient empowerment in this study will occur over 6-months as patients gain the ability to use the StrokeWear technology independently and develop skills to manage their GDM and DAAP.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care + Sham
Description: The intervention will consist in a sham version of the StrokeWear system and usual clinical care under the direction of a clinician. The sham version of the StrokeWear system will include sensing and recording technology to detect GDMs. However, study participants will not receive feedback from the system regarding the GDM counts.
Study: NCT06794554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin Acetate
Description: IV with a 400 mg loading dose on Day 1 of Week 1, followed by 200 mg once weekly, for a total of 26 doses (6 months).
Study: NCT06794177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variable priority dual task training
Description: Variable priority dual task training with balance and walking exercises performed simultaneously with cognitive tasks, twice a week for six weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed priority dual task training
Description: Fixed priority dual task training with balance and walking exercises performed simultaneously with cognitive tasks, twice a week for six weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single task training
Description: Single task training with balance and walking exercises, twice a week for six weeks
Study: NCT06788847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided needle knife dissection
Description: This procedure involves a minimally invasive dissection of the fibrous cords in Dupuytren's Contracture using a needle knife guided by ultrasound imaging. Local anesthesia using 3-5 ml of 1% Lidocaine and 0.25% bupivacaine is administered for patient comfort. The technique aims to improve precision, minimize complications and reduce recurrence.~Device: Sonosite M-Turbo Ultrasound Machine with Linear Probe HFL38x (6-13 MHz) is used for real-time imaging during the procedure.
Study: NCT06794398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-CPR inside a room when the lay responder is alone (no operator for holding the phone)
Description: Participants should find an appropriate smartphone position when they were able to use any objects in their environment. Participants get video-based (vocal and visual) instructions from the dispatcher during the V-CPR situation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-CPR inside a room when the lay responder is alone (no operator for holding the phone)
Description: Participants should find an appropriate smartphone position when they were able to use any objects in their environment. Participants get video-based (vocal and visual) instructions from the dispatcher during the V-CPR situation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-CPR in a yard (outside environment) when the lay responder is alone (no operator for holding the phone)
Description: Participants should find an appropriate smartphone position when they were able to use any objects in their environment. Participants get video-based (vocal and visual) instructions from the dispatcher during the V-CPR situation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-CPR in a yard (outside environment) when the lay responder is alone (no operator for holding the phone)
Description: Participants should find an appropriate smartphone position when they were able to use any objects in their environment. Participants get video-based (vocal and visual) instructions from the dispatcher during the V-CPR situation.
Study: NCT06796205

Intervention type: OTHER
Intervention: Treated zones exposed with Visible Light source
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Treated zones exposed with Visible Light source
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Treated zones exposed with Visible Light source
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Untreated zone exposed with Visible Light source
Description: The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
Study: NCT06796647

Intervention type: DIAGNOSTIC_TEST
Intervention: ESAT6/CFP10 skin test
Description: Each recruited participant would be offered standard tuberculin skin test (TST) and ESAT6/CFP10 (C-TST) skin test on the same day or setting of clinical visit. TST and C-TST would be performed by the Mantoux technique with intradermal injection of 2U purified protein derivative-RT23 on one forearm and 5U (1.0µg/0.1 ml) of recombinant fusion protein ESAT6-CFP10 on the other forearm respectively.
Study: NCT06795477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No MI Help
Description: Participants will complete the medication verification task without any MI help

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No MI Help
Description: Participants will complete the medication verification task without any MI help

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretable MI
Description: Participants receive interpretable machine intelligence assistance to complete the medication verification tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterpretable MI
Description: Participants receive uninterpretable (i.e., black-box) machine intelligence assistance to complete the medication verification tasks.
Study: NCT06792851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kosmos Bladder Volume Algorithm
Description: Participants underwent Kosmos bladder volume assessment by both a nurse and an abdominal sonographer pre-void. Participants voided and measured void volume. Participants underwent Kosmos bladder volume assessment by both a nurse and an abdominal sonographer post-void. Kosmos calculated volume measurements were compared to volume measurements calculated using calipers placed by sonographers by hand.
Study: NCT06797245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RiSolve App
Description: Participants randomized to intervention will be given access to the RiSolve PDTx app for 10 weeks after initial activation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AUGS Patient Handouts
Description: AUGS Overactive Bladder and Pelvic Floor Muscles and Bladder Training Patient Fact Sheets will be provided and reviewed.
Study: NCT06793553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction therapy
Description: 2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction therapy
Description: 2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX
Study: NCT06794047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C tablets, please instruct the patient to swallow with water, 500mg twice daily, morning and evening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets with the same material, flavor, and appearance as the intervention group.
Study: NCT06793982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Joint Injection
Description: Magellan Autologous Concentration System, ISTO Biologics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: 5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
Study: NCT06794073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimodal Thermal Therapy
Description: The high-burden tumor is identified as the target lesion for treatment. A pre-treatment biopsy of the target lesion is performed to obtain tumor tissue. Multimodal ablation therapy of the target lesion is conducted under CT guidance. The treatment procedure follows the tumor ablation protocol using the multimodal therapy radiofrequency temperature-controlled mode.
Study: NCT06241209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PowerPoint program visual stimulation
Description: Moving objects, food, money, and other targets will be presented in the remaining seeing, and hemianopic areas.
Study: NCT06796920

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Upon completion of the initial assessments, a lumbar spinal cord nerve stimulator and pulse generator will be implanted. Following surgery, based on the patient's recovery status, the patient will be transferred to the respective center for rehabilitation within one to two weeks. Afterward, electrical stimulation therapy will be initiated. Stimulation should be applied at least three days per week. Each day, the total stimulation time should be between 4 and 8 hours. Stimulation Modes: Continuous Stimulation: For example, if 6 hours of stimulation are prescribed, the stimulator will run uninterrupted for 6 hours. Intermittent Stimulation: For instance, a cycle of 40 seconds on and 20 seconds off. If a total of 6 hours of active stimulation is needed, the stimulator must remain on for 9 hours in total to accommodate rest intervals.The ranges for each parameter are as follows:Stimulation Frequency: 2 Hz - 2000 Hz, Pulse Width: 20 μs - 1000 μs, Stimulation Amplitude:Voltage: 0 V - 10 v
Study: NCT05969860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Encounter
Description: Receive treatment in clinic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Health Encounter
Description: Receive at-home treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Health Encounter
Description: Receive at-home treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03440086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: abdominal Jackson-Pratt drain
Description: One-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
Study: NCT03988699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tinnitus Implant System
Description: Device will deliver stimulation below hearing thresholds continuously or intermittently.
Study: NCT06083272

Intervention type: DEVICE
Intervention: Vitalthings Guardian M10 fixed and M10 mobile
Description: VitalThings Guardian M10 / M10 mobile (VitalThings, Norway), are the investigational devices. These are the same technical devices made in two versions: one wall-mounted (VitalThings Guardian M10 fixed) and one mounted on a trolley (VitalThings Guardian M10 mobile). The Nox T3s and Nonin will be used as comparator devices.
Study: NCT06795282

Intervention type: DRUG
Intervention: MTA
Description: MTA is primarily composed of tricalcium silicate, dicalcium silicate, bismuth oxide (for radiopacity), and small amounts of calcium sulfate. MTA is highly biocompatible, making it suitable for use in the root canal system and areas in close contact with tissues.

Intervention type: DRUG
Intervention: MTA
Description: MTA is primarily composed of tricalcium silicate, dicalcium silicate, bismuth oxide (for radiopacity), and small amounts of calcium sulfate. MTA is highly biocompatible, making it suitable for use in the root canal system and areas in close contact with tissues.
Study: NCT06792682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose escalation
Description: Three dose groups are preset. The doses are 2.0×10\^6/kg/time, 3.5×10\^6/kg/time and 5.0×10\^6/kg/ time respectively, in accordance with the 3+3 dose escalation principle, and proceed in turn.~Each subject receives conventional treatment plus umbilical cord blood mononuclear cells therapy, with 4 consecutive intravenous infusions of umbilical cord blood mononuclear cells at 1 week intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose extension
Description: According to the safety data of dose escalation stage, one dose group is selected for extension.~Each subject receives conventional treatment plus umbilical cord blood mononuclear cells therapy, with 4 consecutive intravenous infusions of umbilical cord blood mononuclear cells at 1 week intervals.
Study: NCT06796465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie with Progressive Postural Control Exercises
Description: The McKenzie Exercises focus on progressive spinal extension to alleviate back pain. Key steps include Extension in Standing, where patients lean backward and return to a neutral stance; Extension in Lying (Partial Range), involving partial pushups in a prone position; and Extension in Lying (Full Range), where patients fully extend their arms to achieve maximum spinal extension. Each movement is held for 1-2 seconds.~The PPCE program enhances core strength and stability through three stages. In the First Stage (2 weeks), core muscles are trained against gravity using movements like pelvic retroversion, crunches, and glute bridges. The Second Stage (3 weeks) incorporates a Swiss ball to challenge trunk muscles with instability. In the Third Stage (3 weeks), a Swiss ball, stretch bands, and a 5 kg sandbag are used to increase complexity on unstable surfaces. Each stage includes six movements, lasting 5 minutes each, for a total session duration of 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie without Progressive Postural Control Exercises
Description: Subject were treated with McKenzie exercises without the addition of Progressive Postural Control Exercises (PPCE).The exercises included the following:~Standing Extension Exercises: Patients leaned backward from a balanced standing position, arching their back before returning to a neutral stance.~Extension in Lying (Partial Range): Performed in a prone position with hands placed under the shoulders, patients lifted their upper torso in a motion similar to a push-up.~Extension in Lying (Full Range): Similar to the partial range extension, but with fully extended arms, aiming for the maximum tolerated extension. Each movement was sustained for 1-2 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hot Pack
Description: for 10 to 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hot Pack
Description: for 10 to 15 minutes
Study: NCT06795360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: discontinuation of weight loss medication
Description: Participants will be studied right before their injectable weight loss medication runs out, and 3 months later
Study: NCT06796660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nephropathy Formula No. 1
Description: On the basis of integrated treatment for chronic kidney disease (the specific plan is the same as the control group), Nephropathy Formula No. 1 is given orally. The composition and decoction method of the formula are as follows: Bupleurum 10 g, Paeonia lactiflora Pall. 30 g, Scutellaria baicalensis Georgi 12 g, Pinellia ternata (Thunb.) Breit. 12g, Smilax glabra Roxb. 30g, Oldenlandia diffusa (Willd.) Roxb. 30g, Tussilago farfara L. 30g, Poria cocos (Schw.) Wolf 30g, decocted into 300ml, one dose per day, taken warm in two divided doses for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: integrated basic treatment for chronic kidney disease
Description: dietary nutrition adjustment, blood pressure control, blood sugar control, lipid control, anemia treatment, and regulation of water, electrolyte, and acid-base metabolic balance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: integrated basic treatment for chronic kidney disease
Description: dietary nutrition adjustment, blood pressure control, blood sugar control, lipid control, anemia treatment, and regulation of water, electrolyte, and acid-base metabolic balance
Study: NCT06792994

Intervention type: OTHER
Intervention: Observational
Description: The data of this observational trial will be collected as part of routine patient care. Data relating to the time period between the end of participation in the clini-cal first-line trial (CLL13, CLL14, or CLL17) and inclusion in the observational trial will be documented retrospectively at the time point of inclusion in the observa-tional trial. From inclusion in the observational trial, data on survival, long-term efficacy, quality of life, and safety will be collected prospectively
Study: NCT06795594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cheek acupuncture
Description: Cheek Acupuncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sufentanil 2 µg/kg + ondansetron 0.2 mg/kg
Description: The patient-controlled analgesia (PCA) pump held a solution of 2 µg/kg sufentanil and 0.2 mg/kg ondansetron in 100 ml. It infused 2 ml/hour continuously, allowing patients to self-administer an extra 2 ml bolus every 15 minutes if needed. For inadequate pain control, diclofenac sodium suppositories were used as rescue analgesia, depending on individual pain assessments and the requirement for extra relief.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sufentanil 2 µg/kg + ondansetron 0.2 mg/kg
Description: The patient-controlled analgesia (PCA) pump held a solution of 2 µg/kg sufentanil and 0.2 mg/kg ondansetron in 100 ml. It infused 2 ml/hour continuously, allowing patients to self-administer an extra 2 ml bolus every 15 minutes if needed. For inadequate pain control, diclofenac sodium suppositories were used as rescue analgesia, depending on individual pain assessments and the requirement for extra relief.
Study: NCT06795620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose tissue derived mesenchymal Stroma/stem Cells transplantation
Description: Allogeneic adipose tissue-derived stromal cells (AdMSC) (CellReady ® drug) will be administered intramuscularly into the ischemic limb (dose of 90x10\^6 AdMSC) of patients. They will be followed at 1 day, 7 days, 30 days, 90 days, and 180 days after the injection.
Study: NCT05477875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral cannabinoid
Description: dronabinol

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: oral codeine/acetaminophen
Description: 10 tablets of acetaminophen-codeine combination (300-30mg) without refills.
Study: NCT05831709

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: The intervention consists of a supervised exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: The intervention consists of a supervised exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: The intervention consists of a supervised exercise program
Study: NCT06794944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin (POC)
Description: Vancomycin is glycopeptide antibiotic that has broad gram-positive coverage. Patients will receive 125mg PO every 6 hours for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fidaxomicin
Description: Fidaxomicin is a macrolide antibiotic. It is narrow spectrum with potent bactericidal activity specifically against C. difficile. Patients will receive 200mg PO twice daily for 10 days.